CSL slips 6% as Citi slashes target price, Morningstar urges firm to hire new CEO
Shares of Australia's CSL CSL.AX down as much as 6% to A$94.760, on track for their fourth consecutive session of losses, if current trends hold
Citi downgrades company's rating to "neutral" from "buy", cuts target price to A$110 from A$200
Citi downbeat on CSL, says investors will be cautious; trims NPATA estimates by 10% in FY26
Analysts at Morningstar slash revenue and underlying NPAT forecasts for biotech firm by 3% and 9%, respectively, on average over next 10 years
Says it was hard to justify high revenue growth for CSL, given lack of sales momentum
On Monday, Australia's CSL cut its annual profit forecast and warned of a $5 billion impairment
The investment research firm says "hiring credible new CEO and unveiling a compelling vision will be important steps on the path to redemption"
Nine of 16 analysts rate the stock "buy" or higher, seven "hold"; their median PT is A$195 – data compiled by LSEG
YTD, stock down 44.1% including day's moves
Recommended Articles












Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.